.jpeg)
2026-09-14 03:20:04
Bedaquiline is used only in combination for drug-resistant tuberculosis. The classic course is about 24 weeks, while all-oral regimens may run 6 or 9 months; complex resistance can be extended after specialist review based on cultures, susceptibility, and safety.
2026-09-03 06:11:28
Bedaquiline (Sirturo) is used for drug-resistant tuberculosis. This article explains its drug interactions, focusing on CYP3A4 inducers/inhibitors and QT-prolonging agents, to ensure treatment safety.
2026-09-02 07:24:03
Epclusa (Sofosbuvir/Velpatasvir) is the first pan-genotypic direct-acting antiviral regimen for chronic hepatitis C. This article details its dual-target mechanism, comparison with other DAAs, Child-Pugh guided regimens, and special population strategies.
2026-09-02 07:16:43
Lao Biktarvy is a generic version of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) produced in Laos for HIV-1 infection. This article explains its bioequivalence, comparison with other regimens, treatment-naïve and switch strategies, drug interactions, and monitoring.
2026-08-28 06:56:21
Letermovir is used to prevent cytomegalovirus (CMV) infection in transplant patients. This article details the administration methods for tablets and granules, dosage requirements, and drug interactions, emphasizing the importance of following medical advice.
2026-08-26 07:02:04
Pretomanid is a novel anti-tuberculosis agent used in combination with bedaquiline and linezolid as the BPaL regimen for drug-resistant TB. This guide outlines the adverse effect profile of the combination, key safety monitoring points, and clinical management strategies to help clinicians and patients navigate treatment risks.
2026-08-20 02:49:09
Valganciclovir (brand name Valcyte) is the cornerstone oral antiviral agent for the prevention and treatment of cytomegalovirus (CMV) infection following solid organ transplantation. This article provides a structured overview of prophylactic regimens across kidney, heart, and kidney-pancreas transplantation, monitoring and management of myelosuppression, renal function–guided dose adjustments, strategies for addressing antiviral resistance, and practical tips for long-term adherence.
2026-06-29 06:44:46
Pretomanid is a novel nitroimidazole anti-tuberculosis agent and a core component of the BPaL regimen for extensively drug-resistant (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB). This article covers its mechanism of action, efficacy profile, indications and safe use guidelines.
2026-06-08 04:15:26
A detailed analysis of Linezolid's role in treating Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia, comparing its efficacy to Vancomycin and highlighting pharmacokinetic benefits.
2026-05-13 03:19:49
This article dissects the standard duration, long-term risks, and应对 strategies of Pretomanid (core component of BPaL regimen) for drug-resistant TB, highlighting the dangers of exceeding the recommended timeline and offering specialized guidance for patients who have used Pretomanid for three years.
2026-04-27 03:19:03
Cabotegravir Sodium, an advanced integrase strand transfer inhibitor (INSTI), revolutionizes HIV management through its innovative long-acting injectable formulation. Administered every two months, this medication offers a breakthrough in treatment adherence and convenience, particularly for patients requiring flexible regimens.
2026-04-03 06:50:04
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a next-generation fixed-dose combination (FDC) antiretroviral therapy for HIV. It features minimal food dependence, with consistent absorption and antiviral efficacy whether taken with or without food. The core clinical principle is consistent daily dosing at a fixed time to maintain long-term viral suppression.
